Cover Image
市場調查報告書

蛋白激酶CTheta:開發中產品分析

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 368710
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
蛋白激酶CTheta:開發中產品分析 Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 31 Pages
簡介

本報告提供以蛋白激酶CTheta為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

蛋白激酶CTheta 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Astellas Pharma Inc.
  • Celgene Corp
  • CompleGen Inc
  • 武田藥品工業

藥物簡介

暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0797TDB

Summary

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Kinase C Theta Type - Pipeline Review, H1 2017, outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Protein kinase C theta (PKC-θ) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. The molecules developed by companies in Preclinical and Discovery stages are 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Infectious Disease, Oncology, Metabolic Disorders and Undisclosed which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Autoimmune Disorders, Ewing Sarcoma, Heart Transplant Rejection, Inflammation, Insulin Resistance, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Obesity, Prostate Cancer, Rheumatoid Arthritis, Type 2 Diabetes and Unspecified.

Furthermore, this report also reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
  • The report reviews Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)targeted therapeutics and enlists all their major and minor projects
  • The report assesses Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Overview
    • Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Astellas Pharma Inc
    • Celgene Corp
    • CompleGen Inc
    • Takeda Pharmaceutical Company Ltd
  • Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Drug Profiles
    • AS-2521780 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-0739623 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CGX-0471 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CGX-1079 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • englerin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PKC-Theta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Ewing Sarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Protein Kinase C Theta for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Dormant Products
  • Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by AbbVie Inc, H1 2017
  • Pipeline by Astellas Pharma Inc, H1 2017
  • Pipeline by Celgene Corp, H1 2017
  • Pipeline by CompleGen Inc, H1 2017
  • Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
Back to Top